BMRN Q2 2017 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$317M+5.8% YoY

Gross Profit

$261M82.3% margin

Operating Income

-$39M-12.2% margin

Net Income

-$37M-11.6% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+4.5%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

-$29M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$1.2B

Stockholders' Equity

$2.8B

Cash & Equivalents

$355M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$317M	$300M	+5.8%
Gross Profit	$261M	$249M	+5.1%
Operating Income	-$39M	-$573M	+93.2%
Net Income	-$37M	-$419M	+91.2%

Revenue Segments

Product One

$103M33%

Product Three

$102M32%

Product Two

$86M27%

Product Four

$20M6%

Product Five

$5M2%

Product Six

$254,0000%

Geographic Segments

UNITED STATES

$142M45%

Europe

$65M20%

Latin America

$58M18%

Rest Of World

$53M17%